{"schema_version":"1","generated_at":"2026-11-14T23:51:23.509Z","data_as_of":null,"url":"https://www.findmykol.com/kol/jodi-layton","json_url":"https://www.findmykol.com/kol/jodi-layton/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"jodi-layton","name":"Jodi Layton","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Tulane University","institution_url":"https://www.findmykol.com/institution/tulane-university","city":"New Orleans","state":"LA","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"}},"identifiers":{"npi":"1487834552","orcid":"0000-0002-7545-8601","openalex":"A5047780344"},"summary":"Jodi Layton is an Oncology physician affiliated with Tulane University. OpenAlex indexes 73 publications with 526 citations (h-index 9); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":73,"cited_by_count":526,"h_index":9,"latest_activity_year":2025,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT03770455","title":"Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC","phase":"PHASE2","status":"TERMINATED","role":"Overall official","sponsor":"Jodi Layton, MD","source_url":"https://clinicaltrials.gov/study/NCT03770455","trial_url":"https://www.findmykol.com/trial/NCT03770455"}],"source":"trials"},"payments":{"company_count":7,"program_years":{"first":2021,"last":null},"rows_total":14,"shown":3,"withheld":11,"rows":[{"payer":"Novartis Pharmaceuticals Corporation","program_year":2025,"amount_usd":26.62,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1487834552"},{"payer":"Astellas Pharma US Inc","program_year":2025,"amount_usd":25.61,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1487834552"},{"payer":"Astellas Pharma US Inc","program_year":2024,"amount_usd":145.37,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1487834552"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1487834552","source":"payments"},"prescribing":{"data_year":2023,"areas_total":2,"areas_shown":2,"areas":[{"area":"Cancer & immunology","share_pct":75,"classes_total":1,"classes":[{"class":"Cytochrome P450 17A1 Inhibitor","setting":"prescribed","share_pct":75,"drugs":[{"name":"Abiraterone Acetate","share_pct":100}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":25,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":25,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2022,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"ctDNA characterization in mCRPC patients with pathogenic germline variants.","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2025.43.5_suppl.247","status":"verified"},{"title":"Evaluation of ctDNA alterations in lethal mCRPC.","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2025.43.5_suppl.245","status":"verified"},{"title":"Evaluation of ctDNA in patients with mCRPC with liver metastases.","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2024.42.4_suppl.212","status":"verified"},{"title":"Prediction of Resistance to 177 Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers","year":2023,"journal":"Journal of Nuclear Medicine","source_url":"https://doi.org/10.2967/jnumed.123.266167","status":"verified"},{"title":"Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate‐resistant prostate cancer post‐abiraterone and/or enzalutamide","year":2023,"journal":"The Prostate","source_url":"https://doi.org/10.1002/pros.24544","status":"verified"}],"source":"works"},"contact":{"address_1":"150 S LIBERTY ST","city":"New Orleans","state":"LA","zip":"70112","phone":"504-988-6300","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1487834552","source":"identity"},"similar":[{"name":"Roy Weiner","slug":"roy-weiner","institution":"Tulane University","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/roy-weiner","json_url":"https://www.findmykol.com/kol/roy-weiner/profile.json"},{"name":"Vadym Rusnak","slug":"vadym-rusnak","institution":"Tulane University","specialty":"Nephrology","url":"https://www.findmykol.com/kol/vadym-rusnak","json_url":"https://www.findmykol.com/kol/vadym-rusnak/profile.json"},{"name":"Jeffrey Gimble","slug":"jeffrey-gimble","institution":"Tulane University","specialty":"Internal Medicine","url":"https://www.findmykol.com/kol/jeffrey-gimble","json_url":"https://www.findmykol.com/kol/jeffrey-gimble/profile.json"},{"name":"Alan Kaye","slug":"alan-kaye","institution":"Tulane University","specialty":"Pain Medicine","url":"https://www.findmykol.com/kol/alan-kaye","json_url":"https://www.findmykol.com/kol/alan-kaye/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":11,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2019-12-03","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}